ADAMIS PHARMACEUTICALS CORPORATION

Capabilities

Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty biopharmaceutical company that provides high quality, lower-cost solutions for patients, physicians, and healthcare organizations in the multi-billion dollar therapeutic areas of respiratory disease and allergies. The Company’s first approved product, SYMJEPI (epinephrine) Injection is an epinephrine injection pre-filled syringe product for use in the emergency treatment of anaphylaxis. Adamis is also currently developing other specialty pharmaceutical product candidates including APC-1000, an HFA inhaled nasal steroid product for the potential treatment of asthma; APC-6000, a naloxone injection for the potential treatment of opioid overdose.Adamis has been focusing on creating low-cost therapeutic alternatives in large markets to grow its business and to make treatments more affordable for people. Adamis will pursue the 505(b)(2) regulatory approval filings with the FDA to provide alternatives for people.